GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
U

United Therapeutics UTHR · USD

Health Care · US listing · 🇺🇸 United States

Compare

559.10

-3.16%

Close of 19 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

Price performance

Chart by TradingView, with its own licensed prices

United Therapeutics — daily UTHR Delayed
Market value
$27.12bn
Last close × shares
Volume
393.7k
Shares, 19 Nov 2026
Price to earnings
22.1

About United Therapeutics

From its filings with the US Securities and Exchange Commission

SEC filings

United Therapeutics is based in Silver Spring, Maryland and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker UTHR. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported revenue of $3.18bn and net income of $1.33bn. At that date it held total assets of $7.88bn and shareholders' equity of $7.10bn.

In its own words

Founded by our Chairperson and Chief Executive Officer, Martine Rothblatt, to find a cure for her daughter’s life-threatening rare disease, pulmonary arterial hypertension (PAH), United Therapeutics advances therapies for people living with serious diseases with unmet medical needs. Our mission is to transform the treatment of rare diseases and expand the availability of transplantable organs through innovative organ manufacturing technologies.

As a public benefit corporation (PBC), we aim to deliver meaningful impacts for our patients, our people, our shareholders, and other stakeholders. Our public benefit purpose, as outlined in our charter and approved by our shareholders, is to provide a brighter future for patients through (a) the development of novel pharmaceutical therapies; and (b) technologies that expand the availability of transplantable organs.

Tyvaso DPI and Nebulized Tyvaso are also approved by the U.S. Food and Drug Administration (FDA) to treat pulmonary hypertension associated with interstitial lung disease (PH-ILD).

In the United States, we also market and sell an oncology product, Unituxin® (dinutuximab) Injection (Unituxin), which is approved by the FDA for the treatment of high-risk neuroblastoma. Outside the United States, we derive revenues from sales of Nebulized Tyvaso, Remodulin, and Unituxin.

Quoted from its 10-K, filed 25 Feb 2026. Read the filing on SEC.gov ↗

More about United Therapeutics →

Latest on United Therapeutics

Our reporting

Next results

24 Feb 2027

Due on 24 Feb 2027. Analysts expect earnings of 4.95 a share.

Other Health Care listings

Scenario calculator

Try your own numbers. This is arithmetic, not a forecast.

Interactive

Gain or loss

—

Return

—

Leaves out fees, taxes and financing.

Frequently asked questions

What is United Therapeutics's ticker?

United Therapeutics trades as UTHR on its US listing, under ISIN US91307C1027.

What was United Therapeutics's last closing price?

559.10 on 19 Nov 2026. The figure is in USD and is never converted.

When does United Therapeutics next report results?

Results are expected on 24 Feb 2027, according to our data supplier.

Sources and methodology

Chart
TradingView
Close and company data
SEC filings and our data supplier
News
Our reporting

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.